Authors

Latest:

Leveraging Immunotherapy in GI Malignancies: Looking to the Future

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.

Blase Polite, MD

Latest:

Incorporating ctDNA Into Routine Practice: Clinical Pearls

Advice to GI oncologists in the community on using ctDNA testing to detect minimal residual disease and inform treatment decisions in colorectal cancer.

Krystal L. Cleven, MD, MS

Latest:

The Importance of Lung Cancer Screening in Individuals Exposed to the World Trade Center Disaster

Investigators evaluated risk factor–based guidelines and risk model–based strategies for lung cancer screening in World Trade Center–exposed responders.

UCSF Health

Latest:

UC Regents Approve UCSF Proton Therapy Center for Cancer Care

UCSF Life Sciences Building will bring research, innovation, specialty care clinics, and world-class cancer therapy to San Francisco’s central waterfront.

John Shen, MD

Latest:

Dr Shen on the Utility of ARX517 in mCRPC

John Shen, MD, discusses the utility of ARX517 in patients with metastatic castration-resistant prostate cancer.

Yago L. Nieto, MD, PhD

Latest:

Dr. Nieto on High-Dose Chemotherapy and ASCT in R/R Multiple Myeloma

Yago L. Nieto, MD, PhD, professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses findings from a phase 2 trial investigating panobinostat (Farydak), gemcitabine, busulfan, and melphalan plus autologous stem cell transplant (ASCT) in patients with high-risk or relapsed/refractory multiple myeloma.

Daniel King, MD, PhD

Latest:

Dr King on the Need for Less-Toxic Therapies in Advanced Gastrointestinal Cancers

Daniel King, MD, PhD, discusses the need to develop less-toxic regimens for advanced gastrointestinal cancers.

Timothy Cragin Wang, MD

Latest:

Dr. Wang on Challenges With Checkpoint Inhibitors in CRC

Timothy Cragin Wang, MD, discusses the lack of response to checkpoint inhibitors in colorectal cancer.

Hemant S. Murthy, MD

Latest:

Dr Murthy on the Use of CAR T-Cell Therapy in Elderly or Frail Patients With B-Cell Lymphomas

Hemant S. Murthy, MD, discusses the evolving use of CAR T-cell therapy for elderly or frail patients with relapsed/refractory B-cell lymphomas.

Selina M. Luger, MD, FRCPC

Latest:

Women in Oncology: Prioritization and Passionate Legacies

Selina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.

Mina Lobbous, MD, MPH

Latest:

Dr Lobbous on Tucatinib Plus Trastuzumab/Capecitabine in HER2+ Breast Cancer Leptomeningeal Metastases

Mina Lobbous, MD, MPH, on tucatinib plus trastuzumab and capecitabine for leptomeningeal metastases from HER2-positive breast cancer.

Han T. Cun, MD, MS

Latest:

Dr Cun on Molecular Classification in Endometrioid Endometrial Adenocarcinoma

Han T. Cun, MD, MS, discusses the findings from a retrospective comprehensive molecular classification of patients with grade 3 endometrioid endometrial adenocarcinoma.

Nina D'Abreo, MD,

Latest:

Dr D'Abreo on Patient Consideration When Choosing Treatments in HER2+ Breast Cancer

Nina D'Abreo, MD, discusses the importance of considering a patient’s medical history and preferences when deciding on a treatment course in HER2-positive breast cancer and highlights the important role of surgeons within breast cancer treatment.

Quan T. Dang, MD

Latest:

Palliative Care Can Address Gaps in Oncology Landscape

Palliative medicine has evolved to become a standard for high-quality cancer care, helping patients relieve suffering throughout their journey, improving quality of life, and prolonging survivorship.

Elizabeth Wulff-Burchfield, MD

Latest:

Final Thoughts/Looking Forward

Julie E. Chang, MD

Latest:

COVID-19 Pandemic Highlights Underrecognized Vulnerability of Patients With CLL

At the onset of the pandemic, hematology/oncology physicians were challenged in counseling patients with serious underlying malignant conditions about their risk for severe disease due to COVID-19.

Fox Chase Cancer Center

Latest:

Fox Chase Cancer Center Researchers Present Data on Use of Checkpoint Inhibitors and Test Measuring Their Benefit to Patients

The number of patients receiving immune checkpoint inhibitors and PD-L1 testing for treatment of gastroesophageal cancer increased following FDA approval.

Ravin Ratan, MD, MEd

Latest:

Dr. Ratan on the Steps of Diagnosing Desmoid Tumors

Ravin Ratan, MD, MEd, discusses the steps that should be taken to diagnose desmoid tumors.

Bruce Haffty, MD, MS

Latest:

Dr Haffty on Radiation in Node-Positive Breast Cancer That Converts to Node Negative

Bruce G. Haffty, MD, MS, FACR, FASTRO, discusses the use of radiation in node-positive breast cancer patients who convert to node-negative status after neoadjuvant chemotherapy.

Roger Y. Kim, MD, MSCE

Latest:

Immune Checkpoint Inhibitors Extend Survival for Mesothelioma

Immune checkpoint inhibitor therapies have ushered in an exciting new phase of clinical research and treatment for malignant pleural mesothelioma.